About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, March 11th, 2013

The QualityStocks
Daily Stock List


Nano Labs, Corp. (CTLE)

PennyStocks24, Microcap Wire, Black Tie Stock Alerts, The Stock Market Life, Stock Trader, TITAN Stock Alerts, and Wall Street Stallions reported on Nano Labs, Corp. (CTLE), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Nano Labs, Corp. is a nanotechnology research and development company. The Company has a research and development team of scientists, designers, and engineers. Their focus is on creating a portfolio of advanced products that could provide benefits to an array of industries. These industries include consumer products, energy, materials, and healthcare. Founded in 2012, Nano Labs has their headquarters in Detroit, Michigan.

Nano Labs' near-term focus includes Consumer Products (including the manufacture of textiles and electronics), and Energy (including activities relating to generation, distribution, and storage). Their near-term focus also includes Materials (including the manufacture of steel, building products, coatings, and paints), and Healthcare.

Nano Labs' head of Research and Development is Professor Victor Castano, a renowned scientist in nanotechnology. Nanotechnology – in simple terms - involves the manipulation of matter at molecular and atomic levels. Dr. Castano has taught and has conducted research at UNAM, where he is currently a member of the faculty at the Center for Applied Physics and Advanced Technology.

He has also served as visiting scientist at IBM's Thomas J. Watson Research Center. He's written and given hundreds of papers, presentations, and book chapters as an authority in nanotechnology. Additionally, he serves as a Fellow of the Editorial Board of the Research Journal of Chemistry and the Environment.

Last week, Nano Labs presented biological diagnostics test results on a miniaturized tuberculosis biosensor platform. They successfully developed a Point-of-Care biosensor at macro-level and presented industry with proposals for miniaturization and commercialization at large scale. The joint venture proposal is for the development of miniaturized Point-of-Care (PoC) and Lab-on-Chip (LoC) biosensors.

The Company's goal is to establish commercial PoC and LoC biosensors using modern techniques either by applying common Micro-Electro-Mechanical-Systems (MEMS) batch processes, or by using simpler and more modular methods including soft lithography or laser ablation. Nano Labs reports that four unique solutions are proposed. The primary goal is to create a simple, low-cost, high-sensitivity, rapid diagnostic platform capable of being used in remote locations for PoC and LoC monitoring of critical infectious diseases, including tuberculosis (TB).

Additionally, last week, Nano Labs announced that they signed a Letter of Intent (LOI) with AkroStar Peintures of Morocco. This is for the commercialization of their proprietary nano thermal insulation paint coating, NC2012.  Their NC2012 is an insulating paint coating nanotechnology highlighted by its very low thermal conductivity. Currently, Nano Labs is negotiating the non-exclusive rights to market, distribute and generally commercialize the nano coating products developed by the Company in the continent of Africa.

Nano Labs, Corp. (CTLE), closed Monday's trading session at $0.565, up 1.07%, on 849,915 volume with 94 trades. The average volume for the last 60 days is 291,046 and the stock's 52-week low/high is $0.0018/$1.52.

ImageWare Systems, Inc. (IWSY)

TaglichBrothers reported previously on ImageWare Systems, Inc. (IWSY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Headquartered in San Diego, California, ImageWare Systems, Inc. operates in the emerging market for software-based identity management solutions. The Company provides biometric, secure credential, law enforcement and enterprise authorization. Their flagship product is the patented IWS Biometric Engine®. In addition, the Company is using their proven multi-modal biometric advances to deliver innovative mobile capabilities to the wireless, financial services and healthcare sectors. ImageWare Systems identity management products are used by hundreds of police departments in the U.S. and by dozens of government and private sector clients in the U.S., Canada, Mexico, Australia and Japan.

The IWS Biometric Engine® is scalable for small business or global deployment. It is a multi-biometric platform; it is hardware, software and algorithm independent, enabling the enrollment and management of unlimited population sizes. The identification products are used to issue and manage secure credentials. These include national IDs, passports, driver licenses, smart cards and access control credentials.

The law enforcement products provide public safety with integrated mug shot, fingerprint LiveScan and investigative capabilities. The Company additionally provides comprehensive authentication security software. Elements of the IWS Biometric Engine can be used as investigative tools for law enforcement using multiple biometrics and forensic data elements, and to enhance security and authenticity of public and private sector credentials.

Three foundational technologies form the basis of the Company's multi-modal biometric and credentialing offerings. These are Multi-Modal Biometric Matching, Multi-Modal Biometric Capture, and Credential Issuance. ImageWare's products include the IWS CloudID™ Product Suite, the IWS Interactive Messaging System, the PillPhone®, as well as Foundational Products (IWS Biometric Engine®, IWS Desktop Security, IWS EPI Builder, IWS EPI® Suite, and IWS Law Enforcement (formerly CCS)).

Their PillPhone® is a biometrically secured mobile health management application. Its powering is by the IWS Interactive Messaging System. This FDA-cleared application offers interactive medication reminders and information exchange to help healthcare payors, systems, providers and others collaborate with patients in their care outside the medical environment. ImageWare Systems' IWS CloudID™ and IWS Interactive Messaging System platforms are enabling high quality modular, flexible and scalable identity solutions across an array of markets.

ImageWare Systems, Inc. (IWSY), closed Monday's trading session at $0.965, up 1.05%, on 261,705 volume with 133 trades. The average volume for the last 60 days is 65,859 and the stock's 52-week low/high is $0.41/$1.35.

Rio Bravo Oil, Inc. (RIOB)

Today we are highlighting Rio Bravo Oil, Inc. (RIOB), here at the QualityStocks Daily Newsletter.

Rio Bravo Oil, Inc. is an exploration stage company with a strategic focus on the development of proved undeveloped reservoirs, and the expansion of fields by way of unconventional methods and resource development. The Company engages in the acquisition, exploration, and development of oil and natural gas properties in the United States. Rio Bravo Oil is based in Houston, Texas.

The Company is concentrating on developing conventional and unconventional oil fields onshore in the U.S.  Rio Bravo has started to execute their strategy through the acquisition and aggregation of certain working interests (WIs) located within the Luling Edwards, Darst Creek Luling Branyon, and Salt Flat fields in Texas, (collectively referred to as the "Luling Edwards Fields"). Their business strategy is to acquire certain significant WIs and assets with productive Edwards' reservoirs, and to acquire additional rights associated with their targeted leases, to obtain secondary development opportunities.

In February 2012, Rio Bravo Oil announced that on February 13, 2012, they acquired Pan American Oil Company, LLC. With this transaction, Pan American became a wholly owned subsidiary of Rio Bravo Oil. The transaction was the first step in the execution of Rio Bravo's strategy to acquire interests in the oil and gas industry. Pan American had up until that time aggregated certain oil and gas WIs and assets; Pan American has a proportionate interest in certain oil field equipment and improvements.  

As part of the Pan American transaction, Rio Bravo Oil acquired the aggregation through different purchases of a minimum of 63.5 percent WI in the Luling Edwards Fields. In addition, they acquired an option to purchase a 15 percent WI in the Bateman field. Each interest is subject to a 20 percent carried interest in favor of a third party. The Pan American transaction is the first in a series of acquisitions of oil and gas working interests planned by Rio Bravo Oil.

In mid-January 2013, Rio Bravo Oil announced that they completed drilling their first horizontal Edwards formation well, the DG Tiller #4H.  The well demonstrated the presence of hydrocarbons during drilling. It has the potential to produce approximately 150 barrels of oil per day and to produce cumulatively up to approximately 250,000 barrels of oil. The well is within the Salt Flat Field, in Luling, Texas.

The Company also equipped and put into production four inactive Austin Chalk wells.  These wells are each producing several barrels of oil per day.  Rio Bravo is also testing for additional reserves in the DG Tiller #3H.

Rio Bravo Oil, Inc. (RIOB), closed Monday's trading session at $0.85, down 5.56%, on 5,500 volume with 5 trades. The average volume for the last 60 days is 3,460 and the stock's 52-week low/high is $0.64/$1.05.

Seafarer Exploration Corp. (SFRX)

OTCPicks, OTC Advisors, Stock Traders Chat, and Investor Voice reported earlier on Seafarer Exploration Corp. (SFRX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Seafarer Exploration Corp. is an underwater salvage and exploration company whose shares trade on the OTC Markets' OTCQB. Their primary business is to develop the infrastructure necessary to engage in the archaeologically sensitive exploration, documentation, and recovery of historic shipwrecks. The Company's goal is to set the standard in education, conservation, and documentation of historic wreck sites for future generations. Seafarer Exploration has their headquarters in Tampa, Florida.

The Company is primarily focusing on locating and recovering artifacts and cargo from what they believe to be a sunken Spanish ship off the coast of Juno Beach, Florida. Seafarer Management believes that if artifacts and cargo undergo recovery, a portion of the recovered items will be in the form of treasure such as dated coins, gold and silver bullion, and emeralds. In addition, Seafarer has also been mapping and surveying their second site off Lantana Beach, Florida, with positive results. The Company is currently pursuing other projects and wreck sites.

In February 2013, Seafarer Exploration announced that they finalized an agreement with Heartland Treasure Quest, LLC (HTQ) for a third treasure site. HTQ has surveyed, explored, and researched the site and historical archives for more than ten years. Seafarer will now begin the application process for another salvage permit.

Additionally, last month, Seafarer Exploration announced that they completed Phase I on a shipwreck site located near Lantana Beach, Florida. The Company is moving into Phase II, a dig and identify permit that allows Seafarer Exploration to dig and determine assorted artifacts to help identify the ship. The final phase of excavation will be Phase III, full salvage. The Company received a permit from the State of Florida for a shipwreck site located off Lantana Beach, Florida in 2012.

Furthermore, Seafarer Exploration announced a new collaboration with Dr. John de Bry. He is a paleographer specializing in sixteenth- through eighteenth-century French, Spanish and English manuscripts who also serves as the Director of the Center for Historical Archaeology in Melbourne, Florida.  Dr. de Bry has also participated in several field excavation projects in the U.S., the Caribbean, South America and the Philippines. He will provide technical expertise on Seafarer's numerous excavation projects.

Seafarer Exploration Corp. (SFRX), closed Monday's trading session at $0.03, down 11.76%, on 1,697,493 volume with 56 trades. The average volume for the last 60 days is 1,732,973 and the stock's 52-week low/high is $0.0032/$0.04.

LKA International, Inc. (LKAI)

SmallCapVoice and Stockpalooza reported previously on LKA International, Inc. (LKAI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, LKA International, Inc. is a gold mining and exploration company. The Company acquires and develops properties in politically stable jurisdictions; LKA looks for projects in advanced stages of exploration that can generate a cash flow within a relatively short period. Their primary asset is a high-grade gold producing property known as the Golden Wonder Mine located in Colorado. LKA International is based in Gig Harbor, Washington.

Exploration at LKA International's Golden Wonder mine continues to yield excellent ore grades and project profitability. The Company is attempting to re-establish high-grade reserves and return to commercial production. The Golden Wonder Mine is near Lake City, Colorado. It is an extremely high-grade telluride (epithermal) gold deposit.

Concerning the Golden Wonder Exploration Program, since exploration began in 2009, the Company has shipped bulk ore samples containing over 2,942 ounces of gold resulting in net ore sales of $3.3 million.  Average ore grades during this exploration program have exceeded 1.52 ounces (43 grams) per ton. However, LKA International cautions that additional exploration is required and a commercially viable ore reserve has yet to be established.

Last month, LKA International announced that gold ore deliveries by their Golden Wonder mine operator, Coal Creek Construction, exceeded 1,335 ounces during 2012. Ore sales more than offset the Company's exploration expenses for the year. The net value of 2012 gold sales exceeded $1.7 million compared to $851,561 in 2011. All ore shipments in 2012 sold to Kinross' Kettle River milling facility in Republic, Washington.

In addition, in February, LKA International announced that they recently signed an agreement to transfer ownership of their historic Ute Mill site to Hinsdale County, Colorado. This second and most recent agreement sets in motion Phase Two of a two-part arrangement to convey both the town and mill site portions of the Company's inactive silver properties to the County. LKA signed deeds conveying title to the town site last October, 2012.

Phase II of the donation will include the land, reclamation permits, buildings, and structures known as the Ute mill site. It includes the original blacksmith shop, assay lab, powerhouse and mill buildings.

LKA International, Inc. (LKAI), closed Monday's trading session at $0.50, down 1.96%, on 5,500 volume with 2 trades. The average volume for the last 60 days is 11,760 and the stock's 52-week low/high is $0.2001/$0.75.

Titan Medical, Inc. (TITXF)

MadPennyStocks, CoolPennyStocks, BullRally, PennyStockVille, HotOTC, StockRich, and Sharemkt Tips reported previously on Titan Medical, Inc. (TITXF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Based in Toronto, Ontario, Titan Medical, Inc. focuses on the design, development and commercialization of new robotic surgical technologies. The Company currently has under development platforms for single-site and multi-port surgical procedures that are under-served by robotic and non-robotic minimally invasive techniques. Titan Medical actively seeks development and marketing partnerships, research collaborations, and technology in-licensing with other companies, organizations and educational and governmental institutions that will enhance their capabilities, clinical program and product pipeline.

The Company's dedication is to combining the merits of aerospace, medical, and defense technologies to naturally extend and enhance a surgeon's capability. The end objective is to overcome the limitations of fixed port access, limited dexterity and visualization, and limited control systems software. These often result in robotic arm collisions and failed surgery. Titan Medical believes that they have identified the technical hurdles that appear to be present in robotic assisted surgery. Additionally, they also believe that they have solved several of them via their R&D efforts that they're incorporating into Amadeus®.

Presently under development, the Amadeus® system consists of a surgeon-controlled robotic platform. This platform includes a 3D vision system and interactive instruments for performing MIS procedures, and a surgeon workstation that provides the surgeon with an interface to the robotic platform and provides a 3D endoscopic view of inside a patient's body during MIS procedures. The Amadeus® system includes a single-site platform and a multi-port platform having the goal of performing complex procedures directed by a surgical team.

The objective of the development of the Amadeus system is delivering numerous benefits to surgeons. These include higher dexterity instruments, natural control of the instruments, and single incision access for the 3D vision system and the instruments and/or more flexible port access allowing multi-quadrant abdominal procedures. Benefits also include flexible instrument shafts that have multiple degrees of freedom; force feedback for detection of tissue level forces, as well as real-time motion scaling.

Recently, Titan Medical announced results for the fiscal year ended December 31, 2012. Net loss for the fiscal year ended December 31, 2012 was $7,757,244. This is in comparison to a net loss of $16,127,529 for the fiscal year ended December 31, 2011. Net loss for the quarter ended December 31, 2012 was $1,864,102 versus a net loss of $5,159,540 for the quarter ended December 31, 2011. The decrease was due to a shift from a focus on ongoing extensive development of the multi-port platform that currently exists as a prototype, to a focus on the development of the single-site platform.

Titan Medical, Inc. (TITXF), closed Monday's trading session at $0.901, up 4.65%, on 273,187 volume with 121 trades. The average volume for the last 60 days is 83,077 and the stock's 52-week low/high is $0.814/$1.76.

Asia Carbon Industries, Inc. (ACRB)

We are highlighting Asia Carbon Industries, Inc. (ACRB) today, here at the QualityStocks Daily Newsletter.

Asia Carbon Industries, Inc. is a producer of a series of premium carbon black products under the brand name "Great Double Star." The Company, through their variable interest entity, Taiyuan Hongxing Carbon Black, Ltd., manufactures and sells carbon black products in the People's Republic of China (PRC). Asia Carbon established in 2003 in Shanxi, the PRC's highest coal producing province. The Company's shares trade on the OTC Markets' OTCQB. Asia Carbon Industries has their corporate headquarters in New York, New York.

Asia Carbon Industries is one of the top ten carbon black producers in Shanxi province, PRC. The Company has established relationships with a high-profile customer base. Asia Carbon is expanding their manufacturing capacity to meet the growing demand for their products.

Carbon black is a deep, black powder with many applications. It derives from the controlled combustion of coal tar or residual oil feedstock. Carbon black's desirable chemical properties make it a critical raw material for a number of industries.

Carbon black is extensively used within the rubber industry as reinforcing filler. It is used in the paint and coating industry as a coloring agent. In addition, carbon black is used in batteries as a conductive agent. The great majority of carbon black is used by the tire industry, where it can improve rubber's strength, wear resistance, and life span. Consequently, this lowers the overall cost of tire products.

Currently, the Company manufactures three carbon black products - one hard and two soft. Each has a relatively high profit margin. The price of hard carbon black is slightly higher than that of soft carbon black. The demand for hard carbon black is substantially higher than the demand for the soft. In addition, Asia Carbon sells Naphthalene Oil, a byproduct of the Company's manufacturing process.

The global market for carbon black is 9.4 million metric tons. It is forecast to rise 4.3 percent annually through 2013, with the Asia/Pacific region posting the strongest gains (according to a Freedonia Group report).

Asia Carbon Industries, Inc. (ACRB), closed Monday's trading session at $0.163, down 0.61%, on 105,900 volume with 8 trades. The average volume for the last 60 days is 54,411 and the stock's 52-week low/high is $0.13/$0.50.

Primary Petroleum Corp. (PETEF)

We are reporting on Primary Petroleum Corp. (PETEF), here at the QualityStocks Daily Newsletter.

Listed on the OTCQX International, Primary Petroleum Corp. is a junior oil and gas company that has focused a majority of their resources in the acquisition of prospective oil and gas acreage in NW Montana. The Company has a significant land position in the Alberta Basin Bakken Fairway in northwestern Montana. Primary Petroleum has their headquarters in Calgary, Alberta.

Their corporate mandate is to continue to acquire strategic opportunities in the Sedimentary Basins of the Western U.S. and Canada and seek out qualified industry partners to assist in the exploitation and development. The Company currently holds substantial land positions in both an unconventional and conventional oil play.

In the Alberta Basin Bakken Fairway, Primary Petroleum is nearing completion of the $41 million Phase I exploration program. This program is 100 percent funded by their U.S. Major JV Partner. The Phase I program mandate was to evaluate and test the conventional and unconventional formations for commercial hydrocarbons in the area. The target formations explored in the Phase I program were the Sunburst, Madison, Lodgepole, Bakken, Three Forks and Nisku Formations. The Company holds more than 384,000 gross/324,000 net acres (600 gross/506 net sections) in Southern Alberta Basin Bakken prospective area in NW Montana.

Recently, Primary Petroleum gave an update on the JV Program on their Pondera-Teton Prospect in NW Montana. The Company advised that their JV Partner informed them that they do not intend to enter into the Phase II program under the Sales and JV Agreement dated October 17, 2011. The JV Partner will retain their earned working interest in the Pondera-Teton leasehold. They will continue to work with Primary Petroleum to assess options to realize future value in the prospect area.

Primary will continue to evaluate further the data generated by the Phase I program to determine better a go-forward exploration program that will continue to de-risk the multi-formation play. The Company has engaged Image Interpretation Technologies (IIT) to acquire a high-resolution aeromagnetic and gravity survey across the northern half of the project area.

Primary Petroleum Corp. (PETEF), closed Monday's trading session at $0.075, up 7.14%, on 15,740 volume with 2 trades. The average volume for the last 60 days is 51,391 and the stock's 52-week low/high is $0.062/$0.61.


The QualityStocks
Company Corner


VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.80, on 3,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 2,966, and its 52-week low/high is $0.06/$2.84.

VistaGen Therapeutics, Inc. reported today that the company will feature key developments from their pluripotent stem cell-based bioassay system for heart toxicity, CardioSafe 3D™, in a poster presentation at the world's premier toxicology conference, the 52nd Annual Meeting of the Society of Toxicology, in San Antonio, Texas, this March 11, 2013, at 7:30 am PDT. Senior scientist for VSTA, Dr. Hai-Qing Xian, will be on-hand to discuss the results, which confirm that the company's stem cell-based human cardiomyocyte screening systems will indeed provide the improved capabilities and resolution sought after for the ongoing cardiac drug rescue programs, which are anticipated as contributing significantly to the efficient and rapid identification of safer and highly effective new drug therapies.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting

VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D™

VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System

Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.087, off by 3.33%, on 2,525,562 volume with 153 trades. The stock’s average daily volume over the past 60 days is 4,949,501, and its 52-week low/high is $0.0275/$0.155.

Advaxis, Inc. was proud to announce today that lead investigator of the Penn canine study, Dr. Nicola Mason, and scientific founder of Advaxis, Dr. Yvonne Paterson, have received the inaugural University of Pennsylvania One Health Award for their work on Advaxis’ proprietary immunotherapy, ADXS-cHER2, in treating canine osteosarcoma. This award establishes that the Advaxis platform technology can be extended to veterinary use, and the crucial data generated by the Penn study will also help to further development of the company's broader HER-2 targeted immunotherapy for HER-2 overexpressing malignancies in both veterinary and potentially human cancers.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis’ ADXS-cHER2 Immunotherapy Researchers Receive Penn One Health Award for Initiatives in Canine Osteosarcoma

Advaxis Provides Business Outlook for 2013

Advaxis to Provide 2013 Business Outlook on March 6, 2013

Cardium Therapeutics, Inc. (CXM)

The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.165, up 3.12%, on 305,212 volume with 297 trades. The stock’s average daily volume over the past 60 days is 169,247, and its 52-week low/high is $0.15/$0.30.

Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.

Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.

Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer

Cardium Therapeutics, Inc. Company Blog

Cardium Therapeutics, Inc. News:

Cardium's Excellagen® Awarded American Podiatric Medical Association Seal of Approval, Company Also Announces Addition of a Regional Distributor for Excellagen

Cardium Announces Presentation at The 2013 Cell & Gene Therapy Forum

Cardium To Present At Biotech Showcase 2013 Investment Conference And Report On New Cardium Initiatives

Viscount Systems, Inc. (VSYS)

The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.095, up 11.76%, on 36,100 volume with 12 trades. The stock’s average daily volume over the past 60 days is 70,461, and its 52-week low/high is $0.0069/$0.148.

Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.

Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.

Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.

Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer

Viscount Systems, Inc. Company Blog

Viscount Systems, Inc. News:

Viscount Systems to Secure 30 High-Rise Buildings

Viscount Systems Receives New U.S. Government Award

Viscount’s Freedom Installed at Additional BC Government Sites

VistaGen Therapeutics, Inc. (VSTA) to Present Expanded and Improved Applications of Stem-Based Screening System for Heart Toxicity

VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism assays, just announced it will feature key developments involving CardioSafe 3D™, its pluripotent stem cell-based bioassay system for heart toxicity, in a poster presentation at the Society of Toxicology’s 52nd Annual Meeting, the world’s premier toxicology conference, in San Antonio, Texas, today at 7:30 am PDT.

VistaGen’s poster titled “Development of Improved hESC-Based High-Throughput Screening Assays for Cardiotoxicity Assessment,” will be presented by Dr. Hai-Qing Xian, Senior Scientist. The presentation will discuss the following expanded functional and electrophysiological results:

• Optimized differentiation protocols that, without selection, reproducibly yield more than 80% human cardiomyocytes (human heart cells) that function reliably in various established and newly developed assays relevant to cardiac drug effects
• The use of patented technology involving the CD172a cell surface marker, allows the purification of substantially pure (more than 95%) human cardiomyocytes
• The development of a series of fluorescence or luminescence-based high-throughput assays that are used to assess drug-induced: 1) necrosis; 2) apoptosis; 3) mitochondrial toxicity; and 4) oxidative stress of human cardiomyocytes
• New assays are validated using compounds that include: 1) inhibitors of protein kinases; 2) DNA intercalating agents; 3) ion-channel blockers; and 4) compounds that block the surface expression of critical ion-channels
• The assays measured drug effects with high sensitivity, yielding results consistent with known human biology of the compounds

H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer, stated, “I am very pleased with these results, because they confirm that our stem cell-based human cardiomyocyte screening systems will provide improved capabilities and resolution for our cardiac drug rescue programs, which we believe will contribute to the efficient and rapid identification of safer and highly effective new drug therapies.”

For more information on VistaGen and its stem cell-based bioassays, visit www.VistaGen.com

Advaxis, Inc. (ADXS) ADXS-cHER2 Immunotherapy Research Nets Penn One Health Award

Advaxis, a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases, today announced that Dr. Nicola Mason, lead investigator of the Penn canine study, and Dr. Yvonne Paterson, scientific founder of Advaxis, have been given the inaugural University of Pennsylvania One Health Award for their research of Advaxis’ proprietary immunotherapy, ADXS-cHER2, for the treatment of canine osteosarcoma.

The One Health Award, a new accolade for excellence in promoting One Health initiatives and inter-professional education, was established this year by the deans of the four health schools at Penn – Medicine, Nursing, Veterinary Medicine, and Dental Medicine. The award recognizes exemplary contributions toward expanding interdisciplinary education and improving health care.

“Dr. Paterson and I are delighted to have received the One Health Award for our work using ADXS-cHER2 to prevent metastatic disease in dogs with osteosarcoma. Phase 1 of this clinical trial is almost complete and we have been highly encouraged by the lack of adverse effects of this treatment,” stated Dr. Nicola Mason, Chair in Companion Animal Medicine at the University of Pennsylvania School of Veterinary Medicine. “It is too early to comment on the efficacy of the immunotherapy, however, we are encouraged by the data we have obtained so far and are optimistic that immunotherapies such as this one will provide safer and more effective treatment for dogs with cancer in the near future.”

ADXS-cHER2, under the direction of Dr. Nicola Mason, is being used to treat dogs suffering from bone cancer. In this trial, dogs that have undergone standard of care treatment for osteosarcoma; including limb amputation and follow up chemotherapy, and that overexpress the tumor marker HER-2/neu in their tumors, are treated with ADXS-cHER2. This immunotherapy is designed to stimulate the dog’s immune system to attack cancer cells that express the HER-2/neu marker. The goal is to elicit anti-tumor immunity and prolong survival.

Canine osteosarcoma is a leading killer of large breed dogs that causes tumors to form on long leg bones. The current standard of care is immediate amputation followed by chemotherapy; however, the cancer typically metastasizes, most commonly to the lungs, and causes death in 6-12 months in a percentage of afflicted dogs.

“The award winning research of Dr. Mason and Dr. Paterson establishes that the Advaxis platform technology can be extended to veterinary use,” commented Dr. Robert Petit, VP of Clinical Operations and Medical Affairs at Advaxis. “Data from this project will support the further development of our HER-2 targeted immunotherapy against HER-2 overexpressing malignancies in both veterinary and possibly human cancers.”

For more information on Advaxis, visit www.Advaxis.com

The Guitammer Company, Inc. (GTMM) Comes Home

The Guitammer Company’s technology, sold under the ButtKicker brand name, is famous around the world for its remarkable ability to translate low-frequency sounds into tactile chair vibrations that can make a good viewing or listening experience an extraordinary one. It is now used by entertainment and theater companies such as IMAX, Disney, and AMC, as well as by famous musicians. A recent comment from a devoted Guitammer fan sums it up:

“I’m a garage band drummer and have had the opportunity to use the Buttkicker on a few gigs. Definitely a great product all the way from concept through execution. Being able to get a tactile sensation of “thump” without having to blast a monitor to get that sensation is incredibly useful and an all-around better option than hearing damage. Kudos to you and your team for a great tool…”

However, this advanced technology also has a growing place in the home, where it can add a new dimension to personal entertainment. People are now using the Guitammer system, sold under the ButtKicker brand name, for watching movies, music performances, video gaming, and more. It lets friends and family actually feel the special effects, the explosions and crashes, the thundering engines, and the powerful base of music, right in the living room, essentially bringing the excitement of 4D theater home. The company’s low-frequency audio transducers recreate amplified audio signals in the feeling range. They are similar to loudspeakers, but instead of moving a cone and transferring sound waves through the air, they attach to a couch, seat, gaming chair, or even the floor, sending low frequency sound directly into the listener’s body.

In addition, besides working with pre-recorded and sound-augmented presentations, Guitammer’s newly patented broadcast technology, ButtKicker LIVE! will enable the excitement, impact, and feeling of live sporting events to broadcast right along with the sound and video. ButtKicker LIVE! is designed to put the viewer into the action, whether at home or at the event itself. ButtKicker Live! technology is available for cable, satellite, fiber optic, IPTV, and over-the-air broadcast, and has been successfully tested with several major content (sports) providers.

For more information, visit www.Guitammer.com

Loans4Less.com, Inc. (LFLS) and the Challenge of Going National

When California-based online mortgage loan brokerage Loans4Less.com recently reported their selected audited 2012 financials, revealing an impressive 64% jump in annual revenues, in addition to the payoff of $98,000 in revolving debt, it was clear that the company was ready to move forward with its goal of expanding to become a national loan origination platform.

In spite of the fact that the residential mortgage loan market is still somewhat encumbered by strict underwriting requirements, a reaction to the country’s unprecedented real estate crash, Loans4Less is still going strong. Part of this is due to the fact that the company remains focused on solid conforming mortgages, and consider themselves “conforming and jumbo A-paper experts”. Their outlook is optimistic, and they are actively involved in developing a loan origination platform of national scope for joint venture and licensing partners.

Loans4Less obviously knows that expanding their mortgage brokerage capabilities nationally is not as simple as adding more pages to a website. Every state has a unique set of rules relating to residential financing, and the company intends to position itself as the last word for those seeking mortgages and real estate information. Below are just a few of the areas where rules can vary from state to state:

• Loan Flipping – Depending upon how it is defined, loan flipping, the aggressive selling of refinanced loans that are of no real benefit to the consumer, is banned in most states. (This is not to be confused with real estate flipping, which is the purchase and quick resale of properties.)

• Negative Amortization – Loans that require very low payments, but which cause the principal to continue growing, are also banned in many states.

• Prepayment Penalties – Surprisingly, a number of states still allow lenders to include some form of financial penalty if the borrower pays off the loan early.

• Debt To Income Ratio – States vary on how lax lenders can be in determining the ability of the borrower to repay a loan.

For more information, visit www.Loans4Less.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Stock Analyzer




Real Pennies

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251